Page 296 - Read Online

Page 10 of 10 Bracht et al. J Cancer Metastasis Treat 2019;5:22 I http://dx.doi.org/10.20517/2394-4722.2018.111

15. Casillas AL, Toth RK, Sainz AG, Singh N, Desai AA, et al. Hypoxia-Inducible PIM kinase expression promotes resistance to antiangiogenic
agents. Clin Cancer Res 2018;24:169-80.
16. Cen B, Mahajan S, Wang W, Kraft AS. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is
mediated by Pim-1. Cancer Res 2013;73:3402-11.
17. Zhang M, Liu T, Sun H, Weng W, Zhang Q, et al. Pim1 supports human colorectal cancer growth during glucose deprivation by enhancing
the Warburg effect. Cancer Science 2018;109:1468-79.
18. Weirauch U, Beckmann N, Thomas M, Grunweller A, Huber K, et al. Functional role and therapeutic potential of the Pim-1 kinase in colon
carcinoma. Neoplasia 2013;15:783-94.
19. Liu K, Gao H, Wang Q, Wang L, Zhang B, et al. Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3
signaling in colorectal cancer. Cancer Sci 2018;109:1369-81.
20. Braso-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy
response in triple-negative breast cancer. Nat Med 2016;22:1303-13.
21. Zhao W, Qiu R, Li P, Yang J. PIM1: a promising target in patients with triple-negative breast cancer. Med Oncol 2017;34:142.
22. Keane NA, Reidy M, Natoni A, Raab MS, O’Dwyer M. Targeting the Pim kinases in multiple myeloma. Blood Cancer J 2015;5:e325.
23. Koblish H, Li YL, Shin N, Hall L, Wang Q, et al. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and
in combination with anticancer agents, in models of hematologic malignancies. PLoS One 2018;13:e0199108.
24. Kuo HP, Ezell SA, Hsieh S, Schweighofer KJ, Cheung LW, et al. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large
B-cell lymphoma. Am J Cancer Res 2016;6:2489-501.
25. Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R. PIM kinases are a potential prognostic biomarker and therapeutic target
in neuroblastoma. Mol Cancer Ther 2018;17:849-57.
26. An N, Xiong Y, LaRue AC, Kraft AS, Cen B. Activation of Pim kinases is sufficient to promote resistance to MET small-molecule
inhibitors. Cancer Res 2015;75:5318-28.
27. Warfel NA, Sainz AG, Song JH, Kraft AS. PIM kinase inhibitors kill hypoxic tumor cells by reducing Nrf2 signaling and increasing reactive
oxygen species. Mol Cancer Ther 2016;15:1637-47.
28. Jin B, Wang Y, Wu CL, Liu KY, Chen H, et al. PIM-1 modulates cellular senescence and links IL-6 signaling to heterochromatin formation.
Aging Cell 2014;13:879-89.
29. Liu J, Qu X, Shao L, Hu Y, Yu X, et al. Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation.
Cancer Biol Ther 2018;19:160-8.
30. Lee M, Lee KH, Min A, Kim J, Kim S, et al. Pan-Pim kinase inhibitor AZD1208 suppresses tumor growth and synergistically interacts with
akt inhibition in gastric cancer cells. Cancer Res Treat 2018; doi: 10.4143/crt.2017.341.
31. Cen B, Xiong Y, Song JH, Mahajan S, DuPont R, et al. The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase
levels and signaling. Mol Cell Biol 2014;34:2517-32.
32. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
33. Narayan RS, Fedrigo CA, Brands E, Dik R, Stalpers LJ, et al. The allosteric AKT inhibitor MK2206 shows a synergistic interaction with
chemotherapy and radiotherapy in glioblastoma spheroid cultures. BMC Cancer 2017;17:204.
34. Karachaliou N, Cardona AF, Bracht JWP, Aldeguer E, Drozdowskyj A, et al. Integrin-linked kinase (ILK) and src homology 2 domain-
containing phosphatase 2 (SHP2): novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC). EBioMedicine
2019;39:207-14.
35. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J
Natl Compr Canc Netw 2018;16:807-21.
36. Raab MS, Ocio EM, Thomas SK, Günther A, Goh YT, et al. Phase 1 study update of the novel pan-pim kinase inhibitor LGH447 in patients
with relapsed/refractory multiple myeloma. Blood 2014.
37. Paino T, Garcia-Gomez A, Gonzalez-Mendez L, San-Segundo L, Hernandez-Garcia S, et al. The novel Pan-PIM kinase inhibitor,
PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care. Clin Cancer Res
2017;23:225-38.
38. Langowski JL, Holash J, Burger M, Zang R, Zavorotinskaya T, et al. The Pan-PIM kinase inhibitor LGH447 shows activity in PIM2-
dependent multiple myeloma and in AML models. Blood 2013;122:1666.